How to Cite
Abstract
Analyzed the association of functional polymorphisms of VEGFA at positions -2578 of promoter region and at position +936 3'of untranslated region in a group of healthy women and breast cancer patients with the aim to detect informative markers associated with the risk of disease. The study included 395 DNA samples from women with breast cancer and 298 healthy women. Genotyping of polymorphisms of C-2578A and C +936 T VEGFA was performed by restrictase analysis of amplification products (RFLP-analysis). There was revealed the increase of the frequency-2578AA genotype in patients with breast cancer (0R 1.55, 95% CI 1,55-2,29), moreover, the frequency of this genotype increased in the group of patients with a common family history and with breast cancer in close relatives of relatively healthy women (0R = 2,03 95% CI 1,26-3,27 and 0R = 2,22 95% CI 1,13-4,33, respectively). Genotype frequencies of -2578AA /+ 936 SS and -2578SS /+ 936 CT were significantly higher in the group of patients with a factor of family history as compared to the group of patients without it(0R=1,84 95% CI 1,01-3,34 and 0R=2,91 95% CI 1,09-8,05 respectively).References
Banyasz I., Szabo S., Bokodi G., et al. Genetic polymorphisms of vascular endothelial growth factor in severe preeclampsia // Mol Hum Reprod. -2006. Vol.12. P. 233-236.
Bland J., Altman D. Education and debate. The odds ratio. // BMJ. 2000. Vol. 320. P. 1468
Chan L.W., Moses M.A., Goley E., et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression free survival in cancer patients treated with radiation therapy:a longitudinal study of protein kinetics throughout tumor progression and therapy // J Clin Oncol. 2004. Vol. 22. P. 499-506.
Foekens J.A., Peters H.A., Grebenchtchikov N., et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer // Cancer Res. 2001. Vol. 61. P. 5407-5414.
Kawai H., Li H., Chun P., et al. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells // Oncogene. — 2002. — Vol. 21. P. 7730-7739.
Kim J.K., Oh D., Kwak S.Y., et al. Genetic Polymorphism of Vascular Endothelial Growth Factor (VEGF C936T) in the Korean Population // Korean J Biol Sci. — 2003. Vol. 7. P. 261-264.
Lynn K.D., Roland C.L., Brekken R.A. VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer // Cancers. — 2010. — Vol. 2. — P. 970-988.
Renner W., Kotschan S., Hoffmann C., et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels // J Vasc Res. — 2000. — Vol. 37. — P. 443 -448.
Shahbazi M., Fryer A.A., Pravica V., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. // J Am Soc Nephrol. 2002. — Vol. 13. — P. 260-264.
See H.T., Kavanagh J.J., Hu W., Bast R.C. Target therapy for epithelial ovarian cancer: Current status and future prospects // Int J Gynecol Cancer. 2003. — Vol. 13. — P. 701-734.
Yabushita H., Shimazu M., Noguchi M., et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascetic fluid during peritoneal dissemination of ovarian cancer // Oncol. Rep. — 2003. — Vol. 10. — P. 89-95.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...